| 5.02 -0.27 (-5.1%) | 09-18 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |   |
|||
| Targets | 6-month : | 7.07 | 1-year : | 8.05 |
| Resists | First : | 6.05 | Second : | 6.9 |
| Pivot price | 5.85 |
|||
| Supports | First : | 4.69 | Second : | 3.91 |
| MAs | MA(5) : | 5.79 |
MA(20) : | 5.74 |
| MA(100) : | 6.3 |
MA(250) : | 7.67 |
|
| MACD | MACD : | 0 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 17.7 |
D(3) : | 42 |
| RSI | RSI(14): 42.9 |
|||
| 52-week | High : | 13.19 | Low : | 3.81 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ CLNN ] has closed above bottom band by 7.9%. Bollinger Bands are 7.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 5.46 - 5.49 | 5.49 - 5.52 |
| Low: | 4.82 - 4.86 | 4.86 - 4.89 |
| Close: | 4.97 - 5.03 | 5.03 - 5.07 |
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug is CNM-Au8, which is being studied in various clinical trials, including a Phase 2/3 registrational clinical trial for patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; ongoing Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a planned Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company's products also include CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to accelerate wound healing; CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease, such as COVID-19 and to provide immune support for symptom resolution; and CNM-PtAu7, a gold-platinum CSN therapeutic for oncology applications. It also markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.
Mon, 16 Sep 2024
Clene Granted In-Person Meeting With FDA Senior Leadership to Discuss CNM-Au8 Biomarker and Related Clinical and Survival Data - StockTitan
Sat, 31 Aug 2024
Wall Street Analysts Think Clene (CLNN) Could Surge 873.45%: Read This Before Placing a Bet - MSN
Tue, 13 Aug 2024
IBN Coverage: Clene (NASDAQ: CLNN) Makes Strides in Developing CNM-Au8(R) to Address Neurodegenerative Conditions - Yahoo Finance
Fri, 09 Aug 2024
IBN Coverage: Clene (NASDAQ: CLNN) Releases Q2 2024 Financial Results, Provides Updates - Yahoo Finance
Wed, 07 Aug 2024
Clene Inc. (CLNN) Reports Q2 Loss, Lags Revenue Estimates - MSN
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 3.37e+006 (%) |
| Held by Institutions | 33.4 (%) |
| Shares Short | 20 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.44e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -8 % |
| Return on Assets (ttm) | 121.9 % |
| Return on Equity (ttm) | -41.8 % |
| Qtrly Rev. Growth | 442000 % |
| Gross Profit (p.s.) | -137.92 |
| Sales Per Share | -603.46 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -3.1 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -27 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | -30.13 |
| Dividend | 0 |
| Forward Dividend | 137430 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|